Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a671a43d68058477b3c06586b6559db |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-773 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-906 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-545 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
filingDate |
2011-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a65c13b7a062bf9b3cc2a9cd4491a72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_387e9b182ab40d4b1b943e8e467cc516 |
publicationDate |
2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2011093925-A |
titleOfInvention |
Sustained release of anti-infectives |
abstract |
Provided is a therapeutic method in which an aminoglycoside drug used for treating pulmonary infection in a patient with cystic fibrosis (CF) has a low maintenance amount that does not cause nephrotoxicity and ototoxicity even in a patient with renal insufficiency. . Liposomal aminoglycoside formulation comprising aminoglycoside, phosphatidylcholine and sterol, wherein the weight ratio of phosphatidylcholine and sterol to aminoglycoside is 2.5: 1 or less. [Selection figure] None |
priorityDate |
2002-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |